PhRMA Initiatives Propel Direct-to-Patient Model, Novartis Leads with Cosentyx Platform
AI-Generated Summary
The Pharmaceutical Research and Manufacturers of America (PhRMA) is spearheading initiatives to bolster U.S. manufacturing and improve patient access to medicines, including a new AmericasMedicines.com platform to facilitate direct purchases. This move aims to reduce reliance on pharmacy benefit managers and lower patient out-of-pocket costs. Novartis is an early adopter, launching a direct-to-patient platform for its top-selling drug Cosentyx, offering a significant discount directly to cash-paying patients.
In a nutshell
This strategic pivot by PhRMA and major players like Novartis signals a significant industry-led effort to reshape drug distribution and pricing models, aiming to enhance patient access and reduce costs by bypassing traditional intermediaries. Its long-term impact on market dynamics and regulatory frameworks will be a key area to monitor as these direct-to-patient initiatives scale.
Source: Benzinga
